Nderitu, Paul http://orcid.org/0000-0002-8571-0751
Nunez do Rio, Joan M.
Webster, Laura
Mann, Samantha http://orcid.org/0000-0003-0407-4501
Cardoso, M. Jorge http://orcid.org/0000-0003-1284-2558
Modat, Marc
Hopkins, David
Bergeles, Christos http://orcid.org/0000-0002-9152-3194
Jackson, Timothy L.
Article History
Received: 22 February 2024
Accepted: 7 August 2024
First Online: 21 August 2024
Competing interests
: P.N., J.M.N., L.W., D.H., M.J.C., M.M. and C.B. have no conflicts of interest to declare. S.M. has received speaker and advisory board fees from Bayer and Allergan and has received research grants from Novartis. T.J. has received payment as a clinical expert by solicitors acting for REGENERON. T.J. employer (King’s College Hospital) receives funding for participants enrolled on commercial clinical trials of diabetic retinopathy including THR149-002 (OXURION), NEON NPDR (BAYER), RHONE-X (ROCHE) and ALTIMETER (ROCHE).